A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma-Reference-Cited by-同舟云学术

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

Published:2021-08-31 Issue:1 Volume:40 Page:134-141
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Ahn Daniel H.,Uson Junior Pedro Luiz Serrano,Masci Peter,Kosiorek Heidi,Halfdanarson Thorvardur R.,Mody Kabir,Babiker Hani,DeLeon Thomas,Sonbol Mohamad Bassam,Gores Gregory,Smoot Rory,Bekaii-Saab Tanios,Mahipal Amit,Mansfield Aaron,Tran Nguyen H.,Hubbard Joleen M.,Borad Mitesh J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01170-x.pdf

Reference39 articles.

1. Torre LA, Siegel RL, Islami F, Bray F, Jemal A (2018) Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol 16(3):427–437

2. Jarnagin WR, Ruo L, Little SA et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689–1700

3. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

4. Lamarca A, Palmer DH, Wasan HS et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22(5):690–701

5. Paule B, Herelle MO, Rage E et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105–110

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26

2. Emerging Therapies in Management of Cholangiocarcinoma;Cancers;2024-01-31

3. Targeted mutation-based therapy for intrahepatic cholangiocarcinoma;Hepatoma Research;2023-11-15

4. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas;Heliyon;2023-09

5. New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma;Cancers;2023-08-06